Kai-Cheng Chang

Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study

Shih‐Chieh Shao, Kai-Cheng Chang, Ming‐Jui Hung et al. · Cardiovascular Diabetology · 2019 · 84 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study

Huang‐Tz Ou, Kai-Cheng Chang, Chung‐Yi Li et al. · Cardiovascular Diabetology · 2016 · 77 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

APE1 distinguishes DNA substrates in exonucleolytic cleavage by induced space-filling

Tung-Chang Liu, Chun-Ting Lin, Kai-Cheng Chang et al. · Nature Communications · 2021 · 70 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients

Shih‐Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin et al. · Cardiovascular Diabetology · 2020 · 58 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?

Shih‐Chieh Shao, Yi-Han Lin, Kai-Cheng Chang et al. · BMJ Open Diabetes Research & Care · 2019 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17